Compare Nutrien Ltd (NTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Nutrien Ltd trades at $80.95 (market cap $38.47B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Nutrien Ltd is far larger — about 20.7× Recursion Pharmaceuticals Inc's market cap, and Nutrien Ltd pays a 2.73% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NTR | RXRX | |
|---|---|---|
Market Cap | $38.47B | $1.86B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $6.79 |
52-Week Low | $53.64 | $2.84 |
Enterprise Value | $50.28B | $1.38B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $80.68, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, driven by higher fertilizer prices. Analyst consensus is a Moderate Buy with a $76.17 price target, though recent news includes a downgrade to Hold citing cost pressures and volume constraints. Cash flow trends show consistent operational strength but negative net cash flow in recent years.
The outlook is cautiously optimistic, supported by strong potash and nitrogen demand and institutional buying, but risks include cyclical earnings, rising sulfur costs, and volatile agricultural markets. The stock's current price above the consensus target suggests limited near-term upside, requiring monitoring of cost management and volume recovery for sustained growth.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
